1. Academic Validation
  2. Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents

Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents

  • ACS Med Chem Lett. 2010 Aug 24;1(9):504-9. doi: 10.1021/ml100170e.
Zhi-Qiang Yang 1 Kelly-Ann S Schlegel 1 Youheng Shu 1 Thomas S Reger 1 Rowena Cube 1 Christa Mattern 1 Paul J Coleman 1 Jim Small 1 George D Hartman 1 Jeanine Ballard 2 Cuyue Tang 2 Yuhsin Kuo 2 Thomayant Prueksaritanont 2 Cindy E Nuss 3 Scott Doran 3 Steve V Fox 3 Susan L Garson 3 Yuxing Li 3 Richard L Kraus 3 Victor N Uebele 3 Adekemi B Taylor 2 Wei Zeng 2 Wei Fang 2 Cynthia Chavez-Eng 2 Matthew D Troyer 4 Julie Ann Luk 4 Tine Laethem 4 William O Cook 5 John J Renger 3 James C Barrow 1
Affiliations

Affiliations

  • 1 Departments of Medicinal Chemistry.
  • 2 Drug Metabolism and Pharmacokinetics.
  • 3 Depression and Circadian Disorders.
  • 4 Clinical Pharmacology.
  • 5 Toxicology Sciences.
Abstract

A novel phenyl acetamide series of short-acting T-type calcium channel antagonists has been identified and evaluated using in vitro and in vivo assays. Heterocycle substitutions of the 4-position of the phenyl acetamides afforded potent and selective antagonists that exhibited desired short plasma half-lives across preclinical species. Lead compound TTA-A8 emerged as a compound with excellent in vivo efficacy as indicated by its significant modulation of rat sleep architecture in an EEG telemetry model, favorable pharmacokinetic properties, and excellent preclinical safety. TTA-A8 recently progressed into human clinical trials, and in line with our predictions, preliminary studies (n = 12) with a 20 mg oral dose afforded a high C max of 1.82 ± 0.274 μM with an apparent terminal half-life of 3.0 ± 1.1 h.

Keywords

Calcium channel antagonists; T-type calcium channels; electrocorticogram; pharmacokinetics; sleep.

Figures
Products